Search Videos and More

Showing 1 - 12 of 43 results

Previous| 1 | 2 | 3 ...4 |Next


Allogenic Hematopoietic Cell Transplant a Viable Option for all Patients with High-Risk MDS News

Allogenic Hematopoietic Cell Transplant a Viable Option for all Patients with High-Risk MDS

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in MDS across High-Risk genetic subgroups: Genetic analysis of the BMT CTN 1102 study
Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients Should Know News

Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients Should Know

In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Study Uncovers Role of Ultraviolet Radiation in Development of Rare Leukemia in the Skin News

Study Uncovers Role of Ultraviolet Radiation in Development of Rare Leukemia in the Skin

A change of scenery can restore one's outlook, but for some precancerous cells, a journey from the caves of the bone marrow to the sunny climes of the skin can trigger genetic changes that are a harbinger of cancer, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute of MIT and Harvard.
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer News

New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer

A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
Study Unravels a Cause of Resistance to Novel Drug in Patients with Acute Leukemia News

Study Unravels a Cause of Resistance to Novel Drug in Patients with Acute Leukemia

A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
Season 2, Episode 2: Thalidomide and its Second Act in Multiple Myeloma Podcast

Season 2, Episode 2: Thalidomide and its Second Act in Multiple Myeloma

Momentum isn't always one way. And it's not always constant. Sometimes it shoves you sideways, sometimes it stops you in your tracks. And sometimes only sometimes, it drives you to write one of the most astonishing second acts in all of medicine. That's the story of thalidomide.
Smoldering Multiple Myeloma - A Unique New Approach Video

Smoldering Multiple Myeloma - A Unique New Approach

When Deidre was diagnosed with a precursor condition to multiple myeloma she enrolled in a brand-new clinical trial being conducted at Dana-Farber Cancer Institute. Deidre and her doctor, Dana-Farber's Irene Ghobrial, MD, explain more in this video.
Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic Leukemia News

Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic Leukemia

On Thursday, January 19, 2023, the FDA approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of Frailty News

For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of Frailty

A new tool developed by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital outperforms conventional methods for predicting whether certain medications are likely to lead to frailty in older patients with blood cancers who are taking multiple medications, a study being published online today indicates.
In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program News

In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program

The Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Video

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Inhye Ahn, MD, discusses the background and management of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Hodgkin Lymphoma Video

Hodgkin Lymphoma

Ann LaCasce, MD, MMSc, discusses Hodgkin lymphoma and how to approach the different types of Hodgkin patients.

Showing 1 - 12 of 43 results

Previous| 1 | 2 | 3 ...4 |Next